Abstract
The idea of different adrenergic receptors originated with Langley in 1905. He suggested that the receptors contained inhibitory and excitatory receptor substances. Sir Henry Dale (1906) observed the next year that while the excitatory actions of adrenaline were blocked by ergot, the inhibitory ones were not, providing evidence for two types of adrenergic receptors. Then in 1948 Ahlquist published his now classical paper in the American Journal of Physiology where he studied the effect of six sympathetic stimulating drugs and revealed two patterns of response. He termed one pattern the α effects which included vasoconstriction, here adrenaline was most potent, followed by noradrenaline. Secondly there were β effects which included smooth muscle relaxation and cardiac stimulation. Isoprenaline was the most active here, adrenaline was third, and noradrenaline least effective (Ahlquist 1948). The adrenergic receptors have subsequently been further divided into α1, α2, ß 1 and ß 2 receptors (Lefkowitz 1976; Williams and Lefkowitz 1978; Lees 1981; Andersson 1982). The first report of ß adrenoceptor blocking activity came in 1958 when the properties of dichloroisoprenaline were discovered in animal experiments. This drug had powerful intrinsic sympathomimetic activity and while its importance as a pharmacological tool was recognized the therapeutic potential of this new approach was not (Moran and Perkins 1958; Powell and Slater 1958).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB (1980) Elevation of ß-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65: 949–957
Åblad B, Ervik M, Hallgren J, Johnsson G, Sölvell L (1972) Pharmacological effects and serum levels of orally administered alprenolol in man. Eur J Clin Pharmacol 5: 44–52
Åblad B, Ljung B, Sannerstedt R (1976) Haemodynamic effects of ß-adrenoreceptor blockers in hypertension. Drugs 11 [Suppl 1]: 127–134
Adam WR, Meagher EJ, Barter CE (1982) Labetalol, beta blockers and acute Deterioration of chronic airways obstruction. Clin Exp Hypertens A4 (8): 1419–1428
Adolfsson L, Areskog NH; Furberg C, Granath A, Zetterquist S (1972) Synergistic effects of a new ß-adrenergic blocker ( Pindolol) and Isosorbide-dinitrate during exercise in patients with coronary insufficiency. Eur J Clin Pharmacol 5: 37–40
Adolfsson L, Areskog NH, Furberg C, Johnsson G (1974) Effects of single doses of alprenolol and two cardioselective ß-blockers (H87/07 and H93/26) on exercise-induced angina pectoris. Eur J Clin Pharmacol 7: 111–118
Aellig WH (1983) Clinical pharmacology of ß-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol. J Cardiovasc Pharmacol 5: S16–S20
Agarwal AK, Ahuja RC, Chandra M, Gupta NN, Hasan M (1976) A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris. J Int Med Res 4: 410–417
Agostini A, Berfasconi C, Gerli GC, Luzzana M, Rossi-Bernardi L (1973) Oxygen affinity and electrolyte distribution of human blood: changes induced by propranolol. Science 182: 300–301
Ahlmark G, Saetre H, Korsgren M (1974) Reduction of sudden deaths after myocardial infarction. Lancet 2: 1563
Ahlmark G, Saetre H (1976) Long-term treatment with ß-blockers after myocardial infarction. Eur J Clin Pharmacol 10: 77–83
Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586–600
Alcocer L, Aspe J, Arce E, Vieyra J (1982) The effect of carteolol, a new beta-blocker, on angina pectoris. Curr Ther Res 31 (1): 67–73
Alcock SJ, Bond PA (1964) Observations on the toxicity of Alderlin (pronethalol) in laboratory animals. Proc Eur Soc Study Drug Toxicity 4: 30–39
Alderman EL, Coltart DJ, Wettach GE, Harrison DC (1974) Coronary artery syndromes after sudden propranolol withdrawal. Ann Intern Med 81: 625–627
Alderman EL, Davis RO, Crowley JJ, Lopes MG, Brooker JZ, Friedman JP, Graham AF, Matlof HJ, Harrison DC (1975) Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation 51: 964–975
Alonso DR, Scheidt S, Post M, Killip L (1973) Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis: clinical, pathologic and electrocardiographic correlations. Circulation 48: 588–596
Alvan G, Von Bahr C, Seideman P, Sjoqvist F (1982) High plasma concentrations of betareceptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333
Ames RP, Hill P (1978) Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indexes. Clin Sci Mol Med 55: 311S–314S
Amos HE, Brigden WD, McKerron RA (1975) Untoward effects associated with practolol: demonstration of antibody binding to epithelial tissue. Br Med J 1: 598–600
Amsterdam EA, Gorlin R, Wolfson S (1969) Evaluation of long-term use of propranolol in angina pectoris. J Am Med Assoc 210: 103–106
Anastassiades C (1982) Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J 284 (6314): 506
Anavekar SN, Louis WJ, Morgan TO, Doyle AE, Johnston CI (1975) The relationship of plasma levels of pindolol in hypertensive patients to effect on blood pressure, plasmarenin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol 2: 203–212
Andersson K-E (1982) Drugs blocking adrenoceptors. Acta Med Scand [Suppl] 665: 9–17
Andersen MP, Bechsgaard P, Frederiksen J, Hansen DA, Jürgensen HJ, Nielsen B, Pedersen F, Pedersen-Bjergaard O, Rasmussen SL (1979) Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2: 865–868
Andren L, Hansson L, Bjorkman M (1982) Haemodynamic effects of noise exposure before and after bx-selective and nonselective b-adrenoceptor blockade in patients with essential hypertension. Clin Sci 61: 89s–91s
Anonymous (1982) Long-term and short-term beta-blockade after myocardial infarction. Lancet 1: 1159–1161
Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H (1976) Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 39: 118–28
Apthorp GH, Chamberlain DA, Hayward GW (1964) The effects of sympathectomy on the electrocardiogram and effort tolerance in angina pectoris. Br Heart J 26: 218–226
Aravanis C, Michaelides G (1970) Results of the use of a new beta-adrenergic blocker (LB46) in angina pectoris. Acta Cardiol 25: 501–509
Areskog NH, Adolfsson L (1969) Effects of a cardioselective beta-adrenergic blocker (ICI 50172) on exercise in angina pectoris. Br Med J 2: 601–603
Amman K, Ryden L (1982) Comparison of metoprolol and verapamil in the treatment of angina pectoris. Am J Cardiol 49: 821–827
Arnold JMO, McDevitt DG (1982) Interpretation of isoprenaline dose-response curves in the presence of selective and nonselective ß–adrenoceptor blocking drugs. Br J Clin Pharmacol 13: 585 P
Astrom H, Vallin H (1974) Effect of new beta-adrenergic blocking agent, ICI 66082, on exercise haemodynamics and airway resistance in angina pectoris. Br Heart J 36: 1194–1200
Atkins JM, Blomqvist G, Cohen LS, Mitchell JH, Mullins CB (1971) Serial exercise studies in ischaemic heart disease (I.H.D.). Effects of placebo and ß-adrenergic blocking agents. Clin Res 19: 62
Atterhog JH, Duner H, Pernow B (1976) Haemodynamic effect of pindolol with special reference to the resistance and capacitance vessels of the forearm. Acta Med Scand 199: 251–255
Aubert A, Nyberg G, Slaastad R, Tjeldflaat L (1970) Prophylactic treatment of angina pectoris. A double-blind crossover comparison of alprenalol and pentanitrol. Br Med J 1: 203–206
Baber NS, Lewis JA (1982) Confidence in results of beta-blocker postinfarction trials. Br Med J 284: 1749–1750
Baber NS, Wainwright Evans D, Howitt G, Thomas M, Wilson C, Lewis JA, Dawes PM, Handler K, Tuson R (1980) Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia. Br Heart J 44: 96–100
Bala-Subramanian VB, Bowles MJ, Davies AB, Raftery EB (1982) Calcium channel blockade as primary therapy for stable angina pectoris. Am J Cardiol 50: 1158–1163
Barrett AM (1969) A comparison of the effect of (+) propranolol and (+) propranolol in anaesthetised dogs; ß-receptor blocking and haemodynamic action. J Pharmacol 21: 241–247
Bassan MM, Weiler-Ravell D (1983) Effect of a twelve-hour hiatus in propranolol therapy on exercise tolerance in patients with angina pectoris. Am Heart J 105: 234–238
Bassan M, Weiler-Ravell D, Shaley O (1982 b) The additive antianginal action of oral nifedipine in patients receiving propranolol. Magnitude and duration of effect. Circulation 66 (4): 710–716
Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT (1979) Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol 7: 357–363
Battler A, Ross J, Slutsky R, Pflsterer M, Ashburn W, Froelicher V (1979) Improvement of exercise-induced left ventricular dysfunction with oral propranolol in patients with coronary heart disease. Am J Cardiol 44: 318–324
Battock DJ, Alvarez H, Chidsey CA (1969) Effects of propranolol and isosorbide dinitrate on exercise performance and adrenergic activity in patients with angina pectoris. Circulation 39: 157–169
Bauer JH, Brooks CS (1979) The long-term effect of propranolol therapy on renal function. Am J Med 66: 405–410
Bauer JH, Brooks CS, Weinstein I, Wilcox HH, Heimberg M, Burch RN, Barkley R (1981) Effects of diuretic and propranolol on plasma lipoprotein lipids. Clin Pharmacol Ther 30: 35–43
Becker LC, Fortuin NH, Pitt B (1971) Effect of ischaemic and antianginal drugs on the distribution of radioactive microspheres in the canine left ventricle. Circ Res 28: 263–269
Beeley L, Talbot J (1979) Beta-blocker withdrawal syndrome? Lancet 1: 387
Beinart IW, Pearson RM, Cramp DG, Havard CWH (1979) The effect of metoprolol on plasma lipids. Postgrad Med J 55: 709–711
Belton P, O’Dwyer WF, Carmody M, Donohoe J (1980) Propranolol associated hypoglycaemia in non-diabetics. Ir Med J 73: 173
Benaim ME (1972) Asystole after verapamil. Br Med J 2: 169
Benfield GFA, Hunter KR (1982) Oxprenolol, methyldopa and lipids in diabetes mellitus. Br J Clin Pharmacol 13: 219–222
Bennet D, Balcon R, Hoy J, Sowton E (1970) Haemodynamic effects of dextropranolol in acute myocardial infarction. Thorax 25: 86–88
Bennett DH (1982) Acute prolongation of myocardial refractoriness by sotalol. Br Heart J 47 (6): 521–526
Berdeaux A, Da Costa CP, Gamier M, Boissier J-R, Giudicelli J-F (1978) Beta adrenergic blockade, regional left ventricular blood flow and ST-segment elevation in canine experimental myocardial ischaemia. J Pharmacol Exp Ther 205: 646–656
Besterman EMM, Spencer M (1979) Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br J Clin Pharmacol 8 [Suppl 2]205s–209s
Bett JH (1968) Hypotension after oral propranolol. Lancet 1: 302
Betts TA, Alford C (1983) Beta blocking drugs and sleep. A controlled trial. Drugs 25 [Suppl 2]: 268–272
Beumer HM (1974) Adverse effects of ß-adrenergic receptor blocking drugs on respiratory function. Drugs 7: 130–138
Bhat (1982) Beta-blocker heart attack trial research group 1. Mortality results. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247: 1707–1714
Bianchetti MG, Boehringer K, Weidmann P, Link L, Schiffl H, Ziegler WH (1982) Acute effects of prizidolol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension. Eur J Clin Pharmacol 23: 289–296
Bianchi C, Lucchelli PE, Starcich R (1969) Beta blockade and angina pectoris: a controlled multi-centre clinical trial. Pharmacologia Clinica 1: 161–167
Bjorntorp P (1967) The treatment of angina pectoris with a new beta–receptor blocking agent (H56/28). Acta Med Scand 182: 285–291
Bjorntorp P (1968) Treatment of angina pectoris with beta-adrenergic blockade, mode of action. Acta Med Scand 184: 259–262
Bjorntorp P (1971) Treatment of angina pectoris with beta-receptor blocking agents. Effect of long-term treatment with sustained release tablets. Acta Med Scand 189: 299–301
Black JW, Stephenson JS (1962) Pharmacology of a new adrenergic beta–receptor blocking compound ( Nethalide ). Lancet 2: 311–314
Boakes AJ, Prichard BNC (1973) The effect of AH 5158, pindolol, propranolol and d-propranolol on acute exercise tolerance in angina pectoris. Br J Pharmacol 47: 673–674 P
Bobik A, Jennings GL, Korner PI, Ashley P, Jackman G (1979) Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise. Br J Clin Pharmacol 7: 545–549
Bodem G, Grieser H, Eichelbaum M, Gugler R (1974) Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol 7: 249–252
Bodin N-O, Borg K-O, Johansson R, Obianwu H, Svensson R (1974) Absorption, distribution and excretion of alprenolol in man, dog and rat. Acta Pharmacol Toxicol 35: 261–269
Bolli G, De Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P (1982) Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycaemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptors. Diabetes 31: 641–647
Bolli P, Bühler FR, Raeder EA, Amann FW, Meier M, Rogg H, Burckhardt D (1981) Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol. Circulation 64 (6): 1130–1134
Booth RJ, Bullock JY, Wilson JD (1980) Antinuclear antibodies during acebutolol therapy. Br J Clin Pharmacol May 9 (5): 515–7
Booth RJ, Wilson JD, Bullock JY (1982) Adrenergic receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther 31 (5): 555–558
Boothby CB, Garrard CS, Pickering D (1972) Verapamil in cardiac arrhythmias. Br Med J 11: 349
Borg K-O, Carlsson E, Hoffman K-J, Jonsson T-E, Thorin H, Wallin B (1975) Metabolism of metoprolol - (3H) in man, the dog and the rat. Acta Pharmacol Toxicol 36 [Suppl V]: 125–135
Boudoulas H, Lewis RP, Kates RE, Dalamangas G (1977) Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 87: 433–436
Boudoulas H, Lewis RP, Rittgers SE, Leier VC, Vasko JS (1979) Increased diastolic time: a possible important factor in the beneficial effect of propranolol in patients with coronary artery disease. J Cardiovasc Pharmacol 1: 503–513
Boudoulas H, Dervengas S, Fulkerson PK, Bush CA, Lewis RP (1981) Effect of heart rate on diastolic time and left ventricular performance in patients with atrial fibrillation. In: Dietrich (ed) Non-invasive cardiovascular diagnosis, 2nd edn. Wright-PSG, Littleton
Brailovsky D (1974) Timolol Maleate (MK-950). A new beta-blocking agent for the prophylactic management of angina pectoris. A multicenre, multinational, cooperative trial. In: Magnani (ed) Beta-adrenergic blocking agents in the management of hypertension and angina pectoris. Raven, New York, pp 117–137
Brain MC, Caro RT, Kane J, Lyonnais J, Dollery CT (1974) Acute effects of varying doses of propranolol upon oxygen haemoglobin affinity in man. Br J Clin Pharmacol 1: 67–70
Brann EG, Newman DJ (1973) Oxygen affinity in red cells: inability to show membranebound 2, 3-diphosphoglycerate. Science 179: 593
Braunwald E (1971) Control of myocardial oxygen consumption. Physiological and clinical considerations. Am J Cardiol 27: 416–432
Brecht HM, Banthien F, Schoeppe W (1976) Decrease in plasma noradrenaline levels following long-term treatment with pindolol in patients with essential hypertension. Klin Wochenschr 54: 1095–1105
Breckenridge A (1982) Should every survivor of a heart attack be given a beta–blocker? Part II: Evidence from a clinical pharmacological stand point. Br Med J 285: 37–39
Briant RH, Dollery CT, Fenyvesi T, George CF (1973) Assessment of selective beta-adrenoceptor blockade in man. Br J Pharmacol 49: 106–114
Brisse B, Tetsch P, Jacobs W, Bender F (1982) B–adrenoceptor blockade in stress due to oral surgery. Br J Clin Pharmacol 13 [Suppl 2]: 421s–427s
Brown EM, Fedak SA, Woodward CJ, Aurbach GD, Rodbard D (1976) Beta-adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity. J Biol Chem 251: 1239–1246
Brown P, Baddeley H, Read AE, Davis JD, McGarry J (1974) Sclerosing peritonitis, an unusual reaction to a ß-adrenergic blocking drug (practolol). Lancet 2: 1477–1481
Bühler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR (1972) Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin dependent hypertensive diseases. N Engl J Med 287: 1209–1214
Cairns J A, Klassen GA (1981) Intravenous propranolol therapy for acute myocardial infarction in man. Chest 79: 277
Campbell RWF, Murray A, Julian DG (1981) Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Br Heart J 46: 351–357
Carmeliet E, Verdonck R (1967) Interaction between ouabain and butridine, a beta-adrenergic blocking substance on the heart. Eur J Pharmacol 1: 269–277
Carruthers SG (1982) Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol 13: 193S–198S
Castleden CM, George CF (1979) The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 7: 49–54
Challoner DR, Steinberg D (1966) Effect of free fatty acids on the oxygen consumption of perfused rat heart. Am J Physiol 210: 280–286
Chamberlain DA (1966) Effects of ß-adrenergic blockade on heart size Am J Cardiol 18: 321–328
Chamberlain DA, Green KG (1976) Morbidity and mortality in post-infarction patients under long-term treatment with a beta-adrenoceptor blocking agent. Postgrad Med J 52 [Suppl 4]: 153–154
Chester EH, Shwartz HJ, Fleming GM (1981) Adverse effects of propranolol on airway function in non-astmatic chronic obstructive lung disease. Chest 79: 540–544
Christensen NJ, Trap-Jensen J, Svendsen TL, Rasmussen S, Nielsen PE (1978) Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man. Eur J Clin Pharmacol 14: 227–230
Clark BJ (1976) Pharmacology of beta-adrenoceptor blocking agents. In: Saxena PR, Forsyth RP (eds) Beta-adrenoceptor blocking agents. North-Holland, Amsterdam
Clausen N, Damsgaard T, Mellemgaard K (1979) Antihypertensive effect of a non-selective (propranolol) and a cardioselective (metoprolol) ß-adrenoceptor blocking agent at rest and during exercise. Br J Clin Pharmacol 7: 379–383
Cocco G, Sansano C, Hausmann M, Vallini R, Strozzi C, Chu D (1982) A review of the side effects of ß-adrenoceptor blocking drugs on the skin, mucosae and connective tissue. Curr Ther Res 31: 362–378
Cody RJ, Calabrese LH, Clough JD, Tarazi RC, Bravo EL (1979) Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 25 (6): 800–805
Cohn PF, Braunwald E (1980) Chronic coronary artery disease. In: Braunwald E (ed) Heart disease. A textbook of cardiovascular medicine. Saunders, Philadelphia, pp 1387–1436
Coltart DJ (1971) Comparison of effects of propranolol and practolol on exercise tolerance in angina pectoris. Br Heart J 33: 62–64
Coltart DJ, Gibson DG, Shand DG (1971) Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br Med J 1: 490–491
Crawford MH, LeWinter MM, O’Rourke RA, Karliner JS, Ross J (1975) Combined propranolol and digoxin therapy in angina pectoris. Ann Intern Med 83: 449–455
Cruikshank JM (1980) The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 100: 160–178
Cruikshank JM (1981) Beta-blockers, bradycardia and adverse effects. Acta Ther 7: 309–319
Cruikshank JM (1983) How safe are beta-blockers? Drugs 25 [Suppl 2]: 331–340
Cumming AMM, Brown JJ, Fraser R, Lever AF, Morton JJ, Richards DA, Robertson JIS (1979) Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol 8 (4): 359–364
Dale HH (1906) On some physiological actions of ergot. J Physiol (London) 34: 163–206
Daly K, Bergman G, Rothman M, Atkinson L, Jackson G, Jewitt DE (1982) Beneficial effect of adding nifedipine to beta-adrenergie blocking therapy in angina pectoris. Eur Heart J 3: 42–46
Dargie HJ, Lynch PG, Krikler DM, Harris L, Krikler S (1981) Nifedipine and propranolol: a beneficial drug interaction. Am J Med 71: 676–682
Davidson NMcD, Corrall RJM, Shaw TRD, French EB (1976) Observations in man of hypoglycaemia during selective and non-selective beta blockade. Scott Med J 22: 69–72
Davies RO, Mizgala HF, Khan AS (1969) Propranolol-isosorbide dinitrate: combined therapy in angina pectoris. Clin Res 17: 635
Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1: 77–80
Day JL, Metcalfe J, Simpson CN (1982) Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 284: 1145–1148
Dayer P, Kubli A, Kupfer A, Courvoisier F, Ballant L, Fabre J (1982) Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol 13: 750–751
Deacon SP (1978) The effects of atenolol and propranolol upon lipolysis. Br J Clin Pharmacol 5: 123–125
Deacon SP, Karunayake A, Barnett D (1977) Acebutolol, atenolol and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J 2: 1255–1257
Decalmer PBS, Chattarjee SS, Cruickshank JM, Benson MK, Sterling GM (1978) Betablockers and asthma. Br Heart J 40: 184–189
Deitchman D, LaBudde JA, Seidehamel RJ (1983) Bucindolol. In: Scriabine A (ed) New drugs annual: cardiovascular drugs. Raven, New York, pp 1–18
Delage F, Rouleau JR, Labelle J-L, Dagenais G-R (1980) Effects of metoprolol on effort angina during the postprandial state. Clin Pharmacol Ther 27 (6): 763–768
DelBianco PL, Bavazzano A, Frianchi G, Sicuteri F (1966) Pharmacological and therapeutic effects of adrenergic beta blockade. Boll Soc Ital Cardiol 11: 656–659
Diaz RG, Somberg J, Freeman E, Levitt B (1974) Myocardial infarction after propranolol withdrawal. Am Heart J 88: 257–258
DiBianco R, Singh SN, Shah PM, Carter Newton G, Miller RR, Nahormek P, Bortz Costello R, Laddu AR, Gottdiener JS, Fletcher RD (1982) Comparison of the antianginal efficacy of acebutolol and propranolol. A multicenter, randomized, double-blind placebo-controlled study. Circulation 65: 1119–1128
Dintenfass L (1977) Viscosity factors in hypertensive and cardiovascular diseases. Cardiovasc Med 2: 337–354
Distler A, Keim HJ, Cordes U, Philipp T, Wolff HP (1978) Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension. Am J Med 64: 446–451
Dollery CT, Junod AF (1976) Concentration of (-h)-propranolol in isolated, perfused lungs of rat. Br J Pharmacol 57: 67–71
Dominiak P, Grobecker H (1982) Elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of pindolol. Br J Clin Pharmacol 13 [Suppl 2]: 381S–390S
Drayer DE (1976) Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man and accumulation in renal failure. Clin Pharmacokinet 1: 426–443
Drayer DE (1977) Active drug metabolites and renal failure. Am J Med 62: 486–489
Duner H, Pernow B (1973) Haemodynamic effects of ß-receptor blocking agents and digitalis in ischaemic coronary heart disease with angina pectoris. Acta Med Scand 194: 517–523
Durao V, Prata MM, Gongalves LM (1977) Modification of antihypertensive effect of beta-adrenoceptor blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 2: 1005–1007
Dwyer EM, Pepe AJ, Pinkernell BH (1982) Effects of beta-adrenergic blockade with pindolol versus placebo in coronary patients with stable angina pectoris. Am Heart J 103 (5): 830–833
Eastwood JB, Curtis JR, Smith RB (1973) Pharmacodynamics of practolol in chronic renal failure. Br Med J 4: 320–322
Edwards RC, Raftery EB (1976) Haemodynamic effects of long-term oral labetalol. Br J Clin Pharmacol 3 [Suppl 3]: 733–736
Ekberg G, Hansson B-G (1977) Glucose tolerance and insulin release in hypertensive patients treated with the cardioselective ß-receptor blocking agent metoprolol. Acta Med Scand 202: 393–397
Eliasch H, Rosen A, Scott HM (1967) Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Br Heart J 29: 671–683
Eliasson K, Lins L-E, Sundqvist K (1982) Peripheral vasospasm during ß-receptor blockade- a comparison between metoprolol and pindolol. Acta Med Scand [Suppl] 665: 109–112
Ellis EF, Oelz O, Jackson Roberts L, Payne NA, Sweetman BJ, Nies AS, Oates J A (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 193: 1135–1137
Ellis ME, Sahay JN, Chattarjee SS, Cruickshank JM, Ellis SH (1981) Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol 21: 173–176
Erikssen J, Thaulow E, Mundal R, Opstad P, Nitter-Hauge S (1982) Comparison of ß-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol). Br J Clin Pharmacol 13: 201S–209S
Esler M, Jackman G, Leonard P, Skews H, Bobik A, Jennings G (1981) Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. Br J Clin Pharmacol 12: 375–380
Falch DK, Odegaard AE, Norman N (1979) Decreased renal plasma flow during propranolol treatment in essential hypertension. Acta Med Scand 205: 91–95
Felix RH, Ive FA, Dahl MGC (1974) Cutaneous and ocular reactions to practolol. Br Med J 4: 321–324
Fitzgerald JD (1968) Effects of propranolol on blood sugar, insulin and free fatty acids. Diabetologia 5: 339
Fitzgerald JD (1972) Beta adrenergic blocking drugs. Present position and future developments. Acta Cardiol [Suppl] 15: 199–216
Fitzgerald JD (1976) The effect of ß-adrenoceptor antagonists on the morbidity and mortality in cardiovascular disease. Postgrad Med J 52: 770–781
Fitzgerald JD, Ruffin R, Smedstad R, Roberts R, McAinsh J (1978) Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 13: 81–89
Fleckenstein A, Frey M, Fleckenstein-Grün G (1983) Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J 4 [Suppl H]: 43–50
Folgering HThM, Borm JFE, van Haaren RHLM (1982) Metabolic aspects of maximal exercise performance after slow release metoprolol and after atenolol. Eur J Clin Pharmacol 23: 283–288
Forrest WA (1972) A total of 254 cases of angina pectoris treated with oxprenolol in hospital practice - a monitored release study. Br J Clin Pract 26: 217–222
Fox CA (1970) Reduction in the rise of systolic blood pressure during human coitus by the ß-adrenergic blocking agent, propranolol. J Reprod Fertil 22: 587–590
Fox K, Jonathan A, Selwyn A (1980) Combined high-dosage administration of nifedipine and propranolol in patients with angina pectoris. Clin Sci 58: 11P–12 P
Fox KM, Jonathan A, Selwyn AP (1981) The use of propranolol and nifedipine in the medical management of angina pectoris. Clin Cardiol 4: 125–129
Fox KM, Deanfleld J, Krikler S, Ribeiro P, Wright C (1983) The influence of cigarette smoking on the medical management of angina. Drugs 25 [Suppl 2]: 177–180
Frais MA, Bayley TJ (1979) Left ventricular failure with labetalol. Postgrad Med J 55: 567–568
Franco-Morselli R, Baudouin-Legros M, Meyer P (1978) Plasma adrenaline and noradrenaline in essential hypertension and after long-term treatment with ß-adrenoceptor blocking agents. Clin Sci Mol Med 55 [Suppl 4]: 97s–100s
Freestone S, Ramsay LE (1983) Effect of beta-blockade on the pressor response to coffee plus smoking in patients with mild hypertension. Drugs 25 [Suppl 2]: 141–145
Frick MH, Luurila O (1976) Double-blind titrated-dose comparison of metoprolol and propranolol in the treatment of angina pectoris. Ann Clin Res 8: 385–392
Frishman W (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs, Part I. Pharmacodynamic and pharmacokinetic properties. Am Heart J 97: 663–670
Frishman W (1980) Clinical pharmacology of the new beta-adrenergic blocking drugs, Part 9. Nadolol: A new long-acting beta-adrenoceptor. Am Heart J 99: 124–128
Frishman W, Smithen C, Befler B, Kligfield P, Killip T (1975) Non-invasive assessment of clinical response to oral propranolol therapy. Am J Cardiol 35: 635–644
Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, Scheidt S (1978) Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J 95: 169–179
Frishman WH, Kostis J, Strom J, Hossler M, Elkayam U, Goldner S, Silverman R, Davis R, Weinstein J, Sonnenblick E (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J 98: 526–535
Frishman WH, Klein NA, Strom JA, Willens H, LeJemtel TH, Jentzer J, Siegel L, Klein P, Kirschen N, Silverman R, Pollack S, Doyle R, Kirsten E, Sonnenblick EH (1982 a) Superiority of verapamil to propranolol in stable angina pectoris: a double-blind, randomized crossover trial. Circulation 65 (1) Part 11:1-51-1-59
Frisk-Holmberg M, Jorfeldt L, Juhlin-Danfelt A (1977) Influence of long-term anti-hypertensive alprenolol treatment on hemodynamic and metabolic response to prolonged exercise in man. Clin Pharmacol Ther 21: 675
Fulton RM, Green KG (1963) Effect of pronethalol in angina pectoris. Br Med J 2: 1228–1229
Furburg B, Dahlqvist A, Raak A, Wrege U (1978) Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris. Curr Med Res Opin 5: 388–393
Furnival CM, Linden RJ, Snow HM (1970) Inotropic changes in the left ventricle: the effect of changes in heart rate, aortic pressure and end-diastolic pressure. J Physiol 211: 359
George CF, Nagle RE, Pentecost BL (1970) Practolol in treatment of angina pectoris. A double-blind trial. Br Med J 2: 402–404
Gianelly RS, Goldman RH, Treister B, Harrison DC (1967) Propranolol in patients with angina pectoris. Ann Intern Med 67: 1216–1225
Gibelli A, Montanari C, Bellani D, Mandelli V, Sacchetti G (1973) Beta-blocking drugs and human platelet aggregation in vitro. Experimentia 29: 186–187
Gibson DG (1974) Pharmacodynamic properties of ß-adrenergic blocking drugs in man. Drugs 7: 8–38
Gibson DG (1977) Pharmacodynamic properties of ß-adrenoceptor blocking drugs in man. In: Avery GS (ed) ß-adrenoceptor blocking drugs; cardiovascular drugs, vol 2. Adis, Sydney, pp 1–40
Gillam PMS, Prichard BNC (1965) Use of propranolol in angina pectoris. Br Med J 2: 337–339
Gillam PMS, Prichard BNC (1966) Propranolol in the therapy of angina pectoris. Am J Cardiol 18: 366–369
Ginn WM, Orgain ES (1966) Propranolol hydrochloride in the treatment of angina pectoris. JAMA 198: 1214–1216
Gluck Z, Baumgartner G, Weidmann P, Pereim E, Bachmann C, Morsdasini R, Flammer J, Keusch G (1978) Increased ratio between serum B- and A-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med 55: 325s–328s
Godenir JP, Amor M, Cherrier F, Houppe JP, Karcher G, Bertrand A (1983) Atenolol in unstable angina. Clinical results and assessment of left ventricular function by radionuclide angiography. Drugs 25 [Suppl 2]: 172–176
Gokal R, Dornan TL, Ledingham JGG (1979) Peripheral skin necrosis complicating betablockade. Br Med J 1: 721–722
Goldreyer BN (1972) Intracardiac electrocardiography in the analysis and understanding of cardiac arrhythmias. Ann Intern Med 77: 117–136
Goldstein RE, Corash LC, Tallman JF, Lake CR, Hyde J, Smith CC, Capurro NL, Anderson JC (1981) Shortened platelet survival time and enhanced heart rate responses after abrupt withdrawal of propranolol from normal subjects. Am J Cardiol 47: 1115–1122
Gooding PG, Berman E (1974) An evaluation of sotalol, a ß-blocking agent, in patients with angina pectoris. Postgrad Med J 50: 734–736
Graham BR, Littlejohns DW, Prichard BNC, Scales B, Southorn P (1973) Preliminary observations on the human pharmacology of I.C.1.66082 in normal volunteers. Br J Pharmacol 49: 154P–155 P
Grandjean T, Rivier JL (1968) Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba. Br Heart J 30: 50–59
Grandjean T, Hamer NJ, Sowton GE, Melendz L (1966) The effect of propranolol (“Inderal”) on effort tolerance in angina pectoris. Cardiologica 49 [Suppl 2]: 57–65
Grant RHE, Keelan P, Kernohan RJ, Leonard JC, Nancekieville L, Sinclair K (1966) Multicenter trial of propranolol in angina pectoris. Am J Cardiol 18: 361–365
Greefhorst APM, van Herwaarden CLA (1981) Comparative study of the ventilatory effects of three beta±-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol 20: 417–421
Greenblatt DJ, Koch-Weser J (1974) Adverse reactions to ß-adrenergic receptor blocking drugs. A report from the Boston Collaborative Drug Surveillance Program. Drugs 7: 118–129
Greil W (1980) Central nervous system effects. Curr Ther Res 28: 106
Gribbin HR, Baldwin CJ, Tattersfield AE (1979) Quantitative assessment of bronchial ß-adrenoceptor blockade in man. Br J Clin Pharmacol 7: 551–556
Gribbin HR, Mackay AD, Baldwin CJ, Tattersfield AE (1981) Bronchial and cardiac ß-adrenoceptor blockade - a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol 12: 61–65
Griffith DNW, James IM, Newbury PA, Woollard ML (1979) The effect of ß-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmacol 7: 491–494
Gross F (1981) International experience with nadolol, a long-acting ß-blocking agent. In: Gross F (ed) Royal society of medicine international congress and symposium series No 37. Academic, London
Gross GJ, Warltier DC, Hardman HF (1978) Beneficial actions of N-dimethyl propranolol on myocardial oxygen balance and transmural perfusion gradients distal to a severe coronary artery stenosis in the canine heart. Circulation 58: 663–669
Guazzi M, Fiorentini C, Polese A, Olivari M, Magrini F (1976) Antihypertensive action of propranolol in man: lack of evidence for a neural depressive effect. Clin Pharmacol Ther 20: 304–309
Gugler R, Bodem G (1978) Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol 13: 13–16
Gugler R, Herold W, Dengler HJ (1974) Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol 7: 17–24
Halkin H, Vered I, Saginer A, Rabinowitz B (1979) Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris. Eur J Clin Pharmacol 16: 387–391
Halprin S, Frishman W, Kirschner M, Strom J (1980) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part II. Effects of oral labetalol in patients with both angina pectoris and hypertension: a preliminary experience. Am Heart J 99: 388–396
Hampton JR (1981) The use of beta blockers for the reduction of mortality after myocardial infarction. Eur Heart J 2: 259–268
Hampton JR (1982) Should every survivor of a heart attack be given a beta blocker? Part I: Evidence from clinical trials. Br Med J 285: 33–36
Haneda T, Lee T, Ganz W (1973) Metabolic effects of propranolol in the ischaemic myocardium studied by regional sampling. Circulation 48 [Suppl 4]: 174
Hansen PF, Rasmussen PA, Nyberg G (1973) Alprenalol alone and in conjunction with pentanitrol in angina pectoris. Acta Med Scand 193: 419–424
Hansson BG, Hokfelt B (1975) Prolonged treatment with penbutolol (HOE 893d) in patients with moderated hypertension I. Effects on blood pressure and pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol 9: 9–19
Hansson BG, Dymling JF, Hedeland H, Hulthen UL (1977) Long-term treatment of moderated hypertension with the beta-receptor blocking agent metoprolol. Eur J Clin Pharmacol 11: 239–245
Hansson L (1973) Beta-adrenergic blockade in essential hypertension. Effects of propranolol on haemodynamic parameters and plasma renin activity. Acta Med Scand 55 [Suppl 1]: 1–40
Hansteen V, Minichen E, Lorensten E, Anderson A, Strom O, Soiland K, Dyrbekk D, Refsun A-M, Tromsdal A, Knudsen K, Eika C, Bakken J, Smith P, Hoff PI (1982) One year’s treatment with propranolol after myocardial infarction; preliminary report of Norwegian multicentre trial. Br Med J 284: 155–160
Hares P, James IM, Griffith D (1977) The effect of acebutolol on the cerebral circulation of man. Br J Clin Pharmacol 4: 373–375
Harley BJS, Davies RO (1968) Propranolol in the office treatment of angina pectoris. Can Med Assoc J 99: 527–530
Hartling OJ, Noer I, Svendsen TL, Clausen JP, Trap-Jensen J (1980) Selective and nonselective ß-adrenoceptor blockade in the human forearm. Clin Sci 58: 279–286
Heatherington DJ, Comerford MB, Nyberg G, Besterman EMM (1973) Comparison of two adrenergic beta-blocking agents, alprenolol and propranolol, in the treatment of angina pectoris. Br Heart J 35: 320–333
Hebb AR, Goodwin TF, Gunton RW (1968) A new beta-adrenergic blocking agent, propranolol in the treatment of angina pectoris. Can Med Assoc J 98: 246–251
Heck I, Trübestein G, Stumpe KO (1981) Effects of combined alpha- and beta-receptor blockade on peripheral circulation in essential hypertension. Clin Sci 61: 429S–432S
Heel RC, Brodgen GE, Speight TM, Avery GS (1980) Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 20: 1–23
Heel RC, Brogden RN, Speight TM, Avery GS (1981) Penbutolol: a preliminary review of its pharmacological efficacy in hypertension and angina pectoris. Drugs 22: 1–25
Heikkila J, Nieminen MS (1978) Rapid monitoring of regional myocardial ischaemia with echocardiography and ST segment shifts in man. Acta Med Scand [Suppl] 623: 71–95
Hesse B, Pedersen JT (1973) Hypoglycaemia after propranolol in children. Acta Med Scand 193: 551–552
Hickie JB (1970) Alprenolol (Aptin) in angina pectoris. A double-blind multicentre trial. Med JAust 2: 268–272
Hillis WS, Tweddel AC, Murray RG, Lawrie TDV (1980) Comparative study of the effects of penbutolol and propranolol in the treatment of angina pectoris. Arzneimittelforsch 30: 1595–1599
Himms-Hagen J (1972) Effects of catecholamines on metabolism. In: Blaschko H, Muscholl E (eds) Catecholamines. Springer, Berlin Heidelberg New York, pp 363–441 (Handbook of experimental pharmacology, vol 33 )
Hitzenberger G, Fitscha P, Beveridge T, Nuesch E, Pacha W (1982) Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol 13: 217S–222S
Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction. Lancet 2: 823–827
Hoffman BF, Singer DH (1967) Appraisal of the effects of catecholamines on cardiac electrical activity. Ann NY Acad Sci 139: 914–939
Hoffman K-J, Regardh C-G, Aurell M, Ervik H, Jordo L (1980) The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 5: 181–191
Hollenberg NK, Adams DF, McKinstry D, Williams GN, Borucki LJ, Sullivan J (1979) Beta-adrenoceptor blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation. Br J Clin Pharmacol 7 [Suppl 2]: 219–226
Hombach V, Hopp H-W, Braun V, Gil-Sanchez D, Deutsch H, Behrenbeck DW, Tauchert M, Hilger HH (1983) Relevance of physical activity to the antianginal effects of betablockade on supraventricular tachycardia. Drugs 25 [Suppl 2]: 186–192
Horn ME, Prichard BNC (1973) A variable dose comparative trial of propranolol and sotalol in angina pectoris. Br Heart J 35: 555
Houben H, Thien TH, Van’T Laar A (1981) Haemodynamic effects of cigarette smoking during chronic selective and non-selective beta-adrenoceptor blockade in patients with hypertension. Br J Clin Pharmacol 12: 67–72
Hultgren HN, Pfeiffer JF, Angel WW, Bilisoly J (1977) Unstable angina: comparison of medical and surgical management. Am J Cardiol 39: 734–740
Ibrahim MM, Madkour MA, Moussallam R (1980) Effect of atenolol on left ventricular function in hypertensive patients. Circulation 62 (5): 1036–1046
Ingram DM, House AK, Thompson GH, Stacey MC, Castleden WM, Lovegrove FT (1982) Beta-adrenergic blockade and peripheral vascular disease. Med J Aust 1 (12): 509–511
Ingram GIC, Jones RV (1966) The rise in clotting Factor VIII induced in man by adrenaline: effect of alpha and beta-blockers. J Physiol 187: 447–454
Ireland MA, Littler WA (1981) The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients. Br J Clin Pharmacol 12: 363–368
Irving MH, Britton BJ. Wood WG, Padgham C, Carruthers M (1974) Effects of beta-adrenergic blockade on plasma catecholamines in exercise. Nature 248: 531–533
Ishizaki T, Hirayama H, Tawara K, Nakaya H, Sato M, Sato K (1980) Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug. J Pharm Exp Ther 212: 173–181
Jachuck SJ, Bird T, Stephenson J, Jackson ES, Clark F (1977) Practolol-induced autoantibodies and their relation to oculo-cutaneous complications. Postgrad Med J 53 (616): 75–77
Jack DB, Kendall MJ, Wilkins M, Quarterman CP (1983) Oxidation phenotype and betablockers. N Engl J Med 308 (16): 964
Jackson G, Atkinson L, Oram S (1975) Reassessment of failed beta-blocker treatment in angina pectoris by peak-exercise heart rate measurements. Br Med J 3: 616–618
Jackson G, Harry JD, Robinson C, Kitson D, Jewitt DE (1978) Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol. Br Heart J 40: 998–1004
Jaillon P, Weissenburger J, Biour M, Cheymol G, Haegle K, Schecter P, Koch-Weser J (1982) P- and α-adrenoceptor antagonism by medroxolol in healthy volunteers: relationship to dose and plasma concentration. J Cardiovasc Pharm 4: 705–713
Jenkins RM, Nagle RE (1982) The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris. Postgrad Med J 58: 697–700
Johnson SM, Mauritson DR, Corbett JR, Woodward W, Willerson JT, Hillis LD (1981) Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 71: 443–451
Johnsson G (1975) Influence of metoprolol and propranolol on haemodynamic effects induced by adrenaline and physical work. Acta Pharmacol Toxicol 36 [Suppl 5]: 59–68
Johnsson G, Regardh C-G (1976) Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clin Pharmacokinet 1: 233–263
Jones DH, Daniel J, Hamilton CA, Reid JL (1980) Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol. Br J Clin Pharmacol 9: 27–31
Jorgensen CR, Wang K, Wang Y, Gobel FL, Nelson RR, Taylor HL (1973) Effect of propranolol on myocardial oxygen consumption and its haemodynamic correlates during upright exercise. Circulation 48: 1173–1182
Juhlin-Dannfelt A (1982) Metabolic effects of beta-adrenoceptor blockade on skeletal muscle at rest and during exercise. Acta Med Scand [Suppl] 665: 113–115
Juhlin-Dannfelt A, Astrom H, (1979) Influence of beta-adrenoceptor blockade on leg blood flow and lactate release in man. Scand J Clin Lab Invest 39: 179
Julian DG, Jackson FS, Prescott RJ, Szekely P (1982) Controlled trial of sotalol for one year after myocardial infarction. Lancet 1: 1142–1147
Kadish A, Oka Y, Becker R, Frater R, Lin YT, Frishman W (1979) Propranolol withdrawal: cause of post-coronary bypass arrhythmias and hypertension. Circulation 60: 104
Kaijser L, Kaiser P, Karlsson J, Rossner S (1980) Beta-blockers and running. Am Heart J 100 (6 pt I): 943–944
Kaltenbach M, Guldner N (1972) Zur Behandlung der Koronarinsuffizienz mit B-Sympathikolytika. In: Dengler HJ (ed) Die therapeutische Anwendung B-sympathikolytischer Stoffe. Schattauer, Stuttgart, pp 123–141
Keber I, Jerse M, Keber D, Stegnar M (1979) The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease. Br J Clin Pharmacol 7: 287–291
Keelan P (1965) Double-blind trial of propranolol (Inderal) in angina pectoris. Br Med J 1: 897–898
Kelly JG, McGarry K, O’Malley K, O’Brien ET (1982) Bioavailability of labetalol increases with age. Br J Clin Pharmacol 14: 304–305
Kendall MJ, Quarterman CP, Bishop H, Schneider RE (1979) Effects of inflammatory disease on plasma oxprenolol concentrations. Br Med J 2: 465–468
Keyrilainen O, Nyberg G, Uusitalo AJ (1973) Effects of alprenolol and isosorbide dinitrate in angina pectoris. Acta Med Scand 193: 281–292
Khambatta RB (1974) Comparison of a new beta-receptor blocking agent acebutolol (Sectral) and propranolol. Clin Trials J 11 [Suppl 3]: 59–67
Kirsten R, Beintz B, Bohmer D, Nelson K, Roth S, Welzel D (1982) Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity. Br J Clin Pharmacol 13 [Suppl 2]: 397S–406S
Kjekshus KJ, Mjos OD (1973) Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion. J Clin Invest 52: 1770–1778
Kligfeld P, Horner H, Smithen C, Brachenfeld N (1975) Metabolic effect of propranolol on ischaemic myocardium. Circulation 51 [Suppl 2]: 26
Kloner RA, Reimer KA, Jennings RB (1976) Distribution of coronary collateral flow in acute myocardial ischaemic injury: effect of propranolol. Cardiovasc Res 10: 81–90
Kloner RA, Fishbein MC, Cotran RS, Braunwald E, Maroko PR (1977) The effect of propranolol on microvascular injury in acute myocardial ischaemia. Circulation 55: 872–880
Koch G (1976) Combined alpha- and beta-adrenoceptor blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise. Br J Clin Pharmacol 3 [Suppl 3]: 729–732
Koch G, Franz IW, Lohmann FW (1981) Effects of short-term and long-term treatment with cardioselective and non-selective beta receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci 61 [Suppl 7]: 433s–435s
Kolendorf K, Bonnevie-Neilson V, Broch-Moller B (1982) A trial of metoprolol in hypertensive insulin dependent diabetic patients. Acta Med Scand 211 (3): 175–178
Kostis JB, Frishman W, Krieger S, Cosgrove N, Hosier M, Kuo PT (1982 b) Once-a-day administration of pindolol in angina. Clin Pharmacol Ther 31(2):240 (Abstr) B5 240
Krauss XH, Schalekamp MADH, Kolsters G, Zaal GA, Birkenhager WH (1972) Effects of chronic beta-adrenergic blockade on systemic and renal haemodynamic responses to hyperosmotic saline in hypertensive patients. Clin Sci 43: 385–391
Krikler DM, Spurrell RAJ (1974) Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad Med J 50: 447–453
Kristensen BO, Steiness E, Weeke J (1978) Propranolol withdrawal and thyroid hormones in patients with essential hypertension. Clin Pharmacol Ther 23: 624–629
Kumana CR, Marlin GE, Kaye CM, Smith DM (1974) New approach to assessment of cardioselectivity of beta-blocking drugs. Br Med J 4 (5942): 444–447
Kurien VA, Oliver MF (1966) Serum free fatty acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 2: 122–127
Kurien VA, Yates PA, Oliver MF (1969) Free fatty acids, heparin, and arrhythmias during experimental myocardial infarction. Lancet 2: 185–187
Lambert D (1976) Effect of propranolol on mortality in patients with angina. Postgrad Med J 52 [Suppl 4]: 57–60
Lammintausta R, Syvalahti E, Iisalo E, Kanto J, Mantyla R (1977) Selective and non-selective beta-blockade in renin release. Acta Pharmacol Toxicol (Copenh) 41: 489–496
Lands AM, Arnold A, McAuliff FP, Luduena FP, Brown TG (1967) Differentiation of receptor systems activated by sympathomometic amines. Nature 214: 597–598
Langley JN (1905) On the reactions on cells and of nerve endings to certain poisons, chiefly as regards the reaction of striated muscles to nicotine and to curare. J Physiol 33: 374–413
Larsson K (1982) Influence of labetalol, propranolol and practolol in patients with asthma. Eur J Resp Dis 63: 221–230
Lee RJ, Evans DB, Baky SH, Laffan RJ (1975) Pharmacology of nadolol (SQ 11725) a beta-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol 33: 371–382
Leenen FHH (1979) Possible significance of the pharmacological differentiation of betablockers for therapy of hypertension. Br J Clin Pharmacol 7 [Suppl 2]: 173S–184S
Leenen FHH, van der Vijgh AB (1981) Regular propranolol versus slow-release propranolol in angina pectoris. Curr Ther Res 30 (1): 113–121
Leenen FHH, Coenen CHM, Zonderland M, Maas AH (1980) Effects of cardioselective and non-selective beta-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther 28: 12–21
Lees GM (1981) A hithchiker’s guide to the galaxy of adrenoceptors. Br Med J 283 (6285): 173 - 8
Lefkowitz RJ (1976) B-adrenergic receptors: recognition and regulation. N Engl J Med 295: 323–328
Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Niskanen J (1982) Effect of pindolol on serum lipids and lipid metabolizing enzymes. Br J Clin Pharmacol 13 [Suppl 2]: 445S–447S
Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558–1560
Lennard MS, Freestone S, Ramsay LE, Tucker GT, Woods HF (1983) Oxydation phenotype and beta-blockers. N Engl J Med 308 (16): 965
Lichtman MA, Cohen J, Murphy NS, Kearney EA, Whitbeck AA (1974) Effect of propranolol on oxygen binding to haemaglobin in vitro and in vivo. Circulation 49: 881–886
Lijnen PJ, Amery AK, Fagard RH, Reybrouck TM, Moerman EJ, De Schaepdryver AF (1979) The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise. Br J Clin Pharmacol 7: 175–181
Livesley B, Catley PF, Campbell RC, Oram S (1973) Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1: 375–378
Lombardo TA, Rose LR, Taeschler M, Tuluy S, Bing RJ (1953) The effect of exercise on coronary blood flow, myocardial oxygen consumption and cardiac efficiency in man. Circulation 7: 71–78
Lopez-Ovejero J A, Weber MA, Drayer JIM, Sealey JE, Laragh JH (1978) Effects of indomethacin alone and during diuretic or beta-adrenoceptor-blockade therapy on blood pressure and the renin system in essential hypertension. Clin Sci Mol Med 55: 203S–205S
Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ (1974) Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther 16: 761–769
Lown B, Wolf M (1971) Approaches to sudden death from coronary heart disease. Circulation 44: 130–142
Ludbrook P, Karliner JS, Kostuk W, O’Rourke RA (1973) Effects of intravenously administered propranolol on wall motion abnormalities. Am J Cardiol 31: 712–717
Lund-Johansen P (1976 a) Hemodynamic long-term effects of timolol at rest and during exercise in essential hypertension. Acta Med Scand 199:263–267
Lund-Johansen P (1976 b) Haemodynamic long-term effects of a new ß-adrenoceptor blocking drug atenolol (I.C.I. 66082) in essential hypertension. Br J Clin Pharmacol 3:445–451
Lund-Johansen P (1979) Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br J Clin Pharmacol 8 [Suppl 2]:107s-1 lis
Lund-Larsen PG, Sivertssen E (1969) Haemodynamic effects of propranolol (Inderal) and H 56/28 (Aptin) in patients with acute myocardial infarction. A comparative study. Acta Med Scand 186: 187–191
Lynch P, Dargie H, Krikler S, Krikler D (1980) Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine and their combination. Br Med J 281: 184–187
Lyon LJ, Nevins MA (1971) Alprenolol treatment of angina pectoris. JAMA 215: 1669
MacAlpin RN, Kattus AA, Winfield ME (1965) The effect of a ß-adrenergic blocking agent ( Nethalide) and nitroglycerin on exercise tolerance in angina pectoris. Circulation 31: 869–875
Mackie IA, Seal DV, Pescod JM (1977) Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction. Br J Ophthalmol 61: 354–359
Maconochie JG, Richards DA, Woodings EP (1977) Modification of pressor responses induced by “cold”. Br J Clin Pharmacol 4: 389 P
Magnani B, Mantovani B, Brancaleoni M, Gubelli S, Ambrosioni E (1983) Cardioselectivity and partial agonist activity in the angianginal efficacy of the ß-adrenoceptor antagonists. A clinical comparison between atenolol and pindolol. Drugs 25 [Suppl 2]: 166–171
Majid PA, van der Vijgh WJF, de Feijter PJ, Wardeh R, van der Wall EE, Roos JP (1979) Once daily atenolol (Tenormin) in the treatment of angina pectoris. Observations on clinical efficacy, pharmacokinetics and pharmacodynamics. Eur J Cardiol 9: 419–435
Maling TJB, Dollery CT (1979) Changes in blood pressure, heart rate and plasma noradrenaline concentration after sudden withdrawal of propranolol. Br Med J 2: 366–367
Manalan AS, Besch HR Jr, Watanabe AM (1981) Characterization of [3H] (+/-) carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circulation Res 49 (2): 326–336
Man in’t Veld AJ, Schalekamp MADH (1982) How intrinsic sympathomimetic activity modulates the haemodynamic responses to b-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol 13 [Suppl 2]: 245S–257S
Manninen V (1970) Movements of sodium and potassium and their traces in propranololtreated red cells and diaphragm muscles. Acta Physiol Scand 335 [Suppl]: 1–76
Marigold JH, Pounder RE, Pemberton J, Thompson RPH (1982) Propranolol, oxprenolol and sclerosing peritonitis. Br Med J 284: 870
Maroko PR, Braunwald E (1973) Modification of myocardial infarction size after coronary occlusion. Ann Intern Med 79: 720–733
Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Braunwald E (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43: 67–82
Maroko PR, Libby P, Braunwald E (1972) Effects of pharmacologic interventions on left ventricular function in the severely ischaemic heart. Circulation 46 [Suppl 2]: 29
Marshall AJ, Roberts CJC, Barritt DW (1976) Raynaud’s phenomenon as side effect of beta-blockers in hypertension. Br Med J 1: 1498–1499
Marx PG, Reid DS (1979) Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol 8 [Suppl 2]: 233s–238s
McDevitt DG (1977) The assessment of ß-adrenoceptor blocking drugs in man. Br J Clin Pharmacol 4: 413–425
McDevitt DG (1978) Beta-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol 5: 97–99
McDevitt DG, Frisk-Holmberg M, Hollifield JW, Shand DG (1976) Plasma binding and the affinitiy of propranolol for a beta receptor in man. Clin Pharmacol Ther 20: 152–157
McDevitt DG, Colin Brown H, Carruthers SG, Shanks RG (1977) Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther 21: 556–566
McGibney D, Singleton W, Silke B, Taylor SH (1983) Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and nonselective b-adrenoceptor antagonists. Br J Clin Pharmacol 15: 15–19
McGonigle RJS, Williams L, Murphy MJ, Parsons V (1981) Labetalol and lipids. Lancet 1 (8212): 163
Mehta J, Mehta P, Pepine CJ (1978) Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3. Role of tachycardia stress and propranolol. Circulation 58 [No 5]: 881–886
Meier A, Schiffl H, Weidmann P, Mordasini R, Riesen W, Bachmann C (1981) Beta-receptor-blocking agents may reverse or prevent diuretic-induced increases in serum lowdensity lipoprotein in cholesterol. Clin Sci 61: 437s–439s
Meinertz T, Hajorg, Kasfer W, Kersting F, Heinz-Brluing K (1979) Beta-blocker withdrawal syndrome? Lancet 1: 270
Melander A, Danielson K, Schersten B, Wahlin E (1977) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22: 108–112
Mehta J, Cohn JN (1977) Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation 55: 370–375
Michelakis AM, McAllister RG (1972) The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol metab 34: 386–394
Miettinen TA, Vanhanen H, Huttunen JK, Vanhanen H, Huttunen JK, Naukkarinen V, Mattila S, Standberg T, Kumlin T (1982) HDL cholesterol and beta-adrenoceptor blocking agents in a five year multifactorial primary prevention trial. Br J Clin Pharmacol 13 [Suppl 2]: 431S–434S
Miller RR, Olson HG, Amsterdam EA, Mason DT ( 1975 a) Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 293: 416–418
Miller RR, Olson HG, Pratt CM, Amsterdam EA, Mason DT ( 1975 b) Efficacy of betaadrenergic blockade in coronary heart disease: Propranolol in angina pectoris. Clin Pharmacol Ther 18: 598–605
Mitchinson MJ (1972) Some clinical aspects of idiopathic retroperitoneal fibrosis. Br J Surg 59: 58–60
Mizgala HF, Counsell J (1976) Acute coronary syndromes following abrupt cessation of oral propranolol therapy. Can Med Assoc J 114, No. 12: 1123–1126
Mizgala HG, Khan AK, Davies RO (1969) Propranolol in the prophylactic treatment of angina pectoris. Can Med Assoc J 100: 756–764
Mjos OD (1971) Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 50: 1386–1389
Mjos OD, Kjekshus JK, Lekven J (1974) Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischaemic injury during norepinephrine infusion in dogs. J Clin Invest 53: 1290–1299
Moir TW (1972) Subendocardial distribution of coronary blood flow and the effect of antianginal drugs. Circ Res 30: 621–627
Molinoff PB, Aarons RD, Nies AS, Gerber JG, Wolfe BB, Goens MB (1982) Effects of pindolol and propranolol on ß-adrenergic receptors on human lymphocytes. Br J Clin Pharmacol 13 [Suppl 2]: 365s
Moran NC, Perkins ME (1958) Adrenergic blockade of the mammalian heart by a dichloro-analogue of isoproterenol. J Pharmacol Exp Ther 124: 223–237
Morganti A, Pickering TG, Lopez-Ovejero JA, Laragh JH (1979) Contrasting effects of acute beta blockade with propranolol on plasma catecholamines and renin in essential hypertension: a possible basis for the delayed antihypertensive response. Am Heart J 98: 490–494
Morrison SC, Kumana CR, Rudnick KV, Haynes B, Jones NL (1982) Selective and nonselective beta-adrenoceptor blockade in hypertension: responses to changes in posture, cold and exercise. Circulation 65 (6): 1171–1177
Moses JW, Wertheimer JH, Bodenheimer MM, Banka VS, Feldman M, Helfant RH (1981) Efficacy of nifedipine in rest angina refractory to propranolol and nitrates in patients with obstructive coronary artery disease. Ann Intern Med 94: 425–429
M.R.C. Report (1981) Report of Medical Research Council Working Party on mild to moderate hypertension: adverse reactions to bendrofluozide and propranolol for the treatment of mild hypertension. Lancet 2: 539–543
Mueller HS, Ayres S (1976) The “diabetic-like” response of the heart in acute myocardial infarction. Circulation 54 [Suppl 2]: 132
Mueller HS, Ayers SM, Religa A, Evans RG (1974) Propranolol in the treatment of acute myocardial infarction. Effect on myocardial oxygen and hemodynamics. Circulation 49: 1078–1087
Muiesan G, Porcellati C, Renzini V, Brunori CA, Valori C, Gigli G (1970) Relationship between plasma catecholamines and free fatty acid concentrations in patients with acute myocardial infarction. Cardiovasc Res 4: 226
Muiesan G, Alicandri C, Rosei AE, Motolese M, Valori C (1975) Effect of oxprenolol on catecholamines and plasma renin activity: acute response to frusemide in hypertensive patients. Clin Sci Mol Med 48: 85s–88s
Multicentre International Study (1975) Improvement in prognosis of myocardial infarction by long-term beta-adrenoceptor blockade using practolol. Br Med J 3: 735–740
Myers MG, Wisenberg G (1977) Sudden withdrawal of propranolol in patients with angina pectoris. Chest 71: 24–26
Myers MG, Freeman MR, Juma ZA, Wisenberg G (1979) Propranolol withdrawal in angina pectoris. A prospective study. Am Heart J 97: 298–302
Nair DV (1972) A double-blind trial of Visken, LB 46, in the treatment of angina pectoris. Indian Heart J 3 [Suppl 1]: 183–191
Nathan AW, Hellestrand KJ, Bexton RS, Ward DE, Spurrell RA, Camm AJ (1982) Electrophysiological effects of sotalol - just another beta blocker? Br Heart J 47 (6): 515–520
Nattel S, Rangno RE, van Loon G (1979) Mechanism of propranolol withdrawal phenomena. Circulation 59: 1158–1164
Nayler WG (1981) Beta blockers in experimental myocardial infarction. Acta Med Scand [Suppl] 651: 139–145
Nayler WG, Mclnnes I, Swann JB, Carson V, Lowe TE (1967) Effect of propranolol, a beta-adrenergic antagonist, on blood flow in the coronary and other vascular fields. Am Heart J 73: 207–216
Neely JR, Rovetto MJ, Oram JF (1972) Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15: 289–329
Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor HL (1974) Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. Circulation 50: 1179–1189
Nestel PJ (1966) Evaluation of propranolol (Inderal) in the treatment of angina pectoris. Med J Aust 2: 1274–1276
Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J (1982) Sotalol prolongation of the QTc interval in hypertensive patients. Clin Pharmacol Ther 32 (l): 25–32
Nicotero J A, Beamer V, Moutsos SE, Shapiro P (1968) Effects of propranolol on pressor responses to noxious stimuli in hypertensive patients. Am J Cardiol 22: 657–666
Nies AS, Shand DG (1975) Clinical Pharmacology of propranolol. Circulation 52: 6–15
Nilsson A, Hansson B-G, Hokfelt B (1978) Effect of metoprolol on blood glycerol, free fatty acids, triglycerides and glucose in relation to plasma catecholamines in hypertensive patients at rest and following submaximal work. Eur J Clin Pharmacol 13: 5–8
Norris RM, Sammel NL, Clarke ED, Brandt PWT (1980) Treatment of acute myocardial infarction with propranolol. Br Heart J 43: 617–622
Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807
Nyberg G (1977) Blood pressure and heart rate during sustained handgrip in hypertensive patients taking placebo, a nonselective beta-blocker (propranolol) and a selective betablocker (metoprolol). Curr Ther Res 22: 828–838
Nyberg G (1979) Effect of beta-adrenergic blockade on haemodynamic responses to dynamic and isometric exercise in angina pectoris. Eur J Clin Pharmacol 15: 381–388
Nyberg G, Berglund G (1982) Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients. Acta Med Scand [Suppl] 665: 93–101
Nyberg G, Graham RM, Stokes GS (1977) The effect of mental arithmetic in normotensive and hypertensive subjects and its modification by beta-adrenoceptor blockade. Br J Clin Pharmacol 4: 469–474
Obeid A, Spear R, Mookherjee S, Warner R, Eich R (1976) The effects of propranolol on myocardial energy stores during myocardial ischaemia in dogs. Circulation 54 [Suppl 2]: 159
Odenthal K-P (1983) Zur Pharmakologie von Carteolol. Drug Res 331 (2 a): 281–285
Oh VM, Kaye CM, Warrington SJ, Taylor EA, Wadsworth J (1978) Studies of cardioselectivity and partial agonist activity in beta adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. Br J Clin Pharmacol 5: 107–120
Ohlsson O, Lindell S-E (1981) The effects of pindolol and prazosin on hand blood flow in patients with cold extremities and on treatment with beta-blockers. Acta Med Scand 210: 217–219
Ohnhaus EE, Nuesch E, Meier J, Kalberer F (1974) Pharmacokinetics of unlabelled and 14-C labelled pindolol in uraemia. Eur J Clin Pharmacol 7: 25–29
Olesen J, Hougard K, Hertz M (1978) Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man. Stroke 9: 344–349
O’Malley K, O’Callaghan WG, Laher MS, McGarry K, O’Brien E (1983) Beta-adrenoceptor blocking drugs and renal blood flow with special reference to the elderly. Drugs 25 [Suppl 2]: 103–107
Opie LH (1975) Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction: relation to myocardial ischaemia and infarct size. Am J Cardiol 36: 938–953
Opie LH (1976) Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 52 [Suppl 4]: 124–132
Opie LH (1980) Drugs and the heart III. Calcium antagonists. Lancet 1: 806–810
Opie LH, Thomas M (1976) Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 52 [Suppl]: 124–133
Oski FA, Miller LD, Delivoria-Papadopoulos M, Manchester JH, Shelburne JC (1972)
Oxygen affinity in red cells: changes induced in vivo by propranolol. Science 175:1372–1373
Page DL, Caulfield JB, Kastor JA, de Sanctis RW, Sanders CA (1971) Myocardial changes associated with cardiogenic shock. N Engl J Med 285: 133–137
Pantano JA, Lee Y-C (1976) Abrupt propranolol withdrawal and myocardial contractility. Arch Intern Med 136: 867–871
Parker JO, Di Giorgi S, West RO (1966) A hemodynamic study of acute coronary insufficiency precipitated by exercise. Am J Cardiol 17: 470–483
Parker JO, West RO, Di Giorgi S (1971) The effect of nitroglycerin on coronary blood flow and the hemodynamic response to exercise in coronary artery disease. Am J Cardiol 27: 59–65
Parker JO, Porter A, Parker JD (1982) Propranolol in angina pectoris: comparison of longacting and standard-formulation propranolol. Circulation 65: 1351–1355
Parratt JR, Grayson J (1966) Myocardial vascular reactivity after beta-adrenergic blockade. Lancet 1: 338–340
Pasotti C, Capra A, Fiorella G, Vibelli C, Chierichetti SM (1982) Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Br J Clin Pharmacol 13 [Suppl 2]: 435S–439S
Pasternack A, Porsti P, Poyhonen L (1982) Effects of pindolol and propranolol on renal function of patients with hypertension. Br J Clin Pharmacol 13 [Suppl 2]: 241S–244S
Patrick JM, Pearson SB (1980) Beta-adrenoceptor blockade and ventilation in man. Br J Clin Pharmacol 10: 624–625
Pedersen OL, Mikkelsen E, Nieseln JL, Christensen NJ (1979) Abrupt withdrawal of betablocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol 15: 215–217
Pelides LJ, Reid DS, Thomas M, Shillingford JP (1972) Inhibition by ß-blockade of the ST segment elevation after acute myocardial infarction in man. Cardiovasc Res 6: 295–301
Pendleton RG, Newman DJ, Sherman SS, Brann EG, Maya WE (1972) Effect of propranolol upon the haemoglobin-oxygen dissociation curve. J Pharmacol Exp Ther 180: 647–656
Perks WH, Chatterjee SS, Croxson RS, Cruickshank JM (1978) Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction. Br J Clin Pharmacol 5: 101–106
Peter T, Heng MK, Singh BN, Ambler P, Nisbet H, Elliott R, Norris RM (1978) Failure of high doses of propranolol to reduce experimental myocardial ischemic damage. Circulation 57: 534–540
Phibbs CM, Van Tyn RA, Maclean LD (1961) Vulnerability of the dog heart to ventricular fibrillation: a comparative study of chronic ischaemia and three myocardial revascularization procedures. J Thorac Cardiovasc Surg 42: 228–235
Phillips DK (1980) Chemistry of alpha- and beta-adrenoceptor agonists and antagonists. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 3–61 (Handbook of experimental pharmacology, vol 54/1)
Pine M, Favrot L, Smith S, McDonald K, Chidsey CA (1975) Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation 52: 886–893
Pitt B, Craven P (1970) Effect of propranolol on regional myocardial blood flow in ischaemia. Cardiovasc Res 4: 176–179
Planz G, Planz R (1980) Influence of propranolol on catecholamine concentration in blood of normotensive man during physical exercise and dependence of the drug effect on dosage intervals. Arch Int Pharmacodyn Ther [Suppl] 1: 58–66
Planz G, Planz R (1981) Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise. Eur J Clin Pharmacol 19: 83–88
Podolsky S, Pattavina G (1973) Hyperosmolar non-ketotic diabetic coma: a complication of propranolol therapy. Metabolism 22: 685–693
Podrid PJ, Lown B (1982) Pindolol for ventricular arrhythmia. Am Heart J 104 (2 Part II): 491–496
Potter DE (1981) Effects of adrenergic activators and inhibitors of the endocrine system. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 161–211 (Handbook of experimental pharmacology, vol 54/1)
Powell CE, Slater IH (1958) Blocking of inhibitory adrenergic receptors by a dichloroanalog of isoproterenol. J Pharmacol Exp Ther 122: 480–488
Prager G (1979) Angina pectoris: effective therapy once daily. J Int Med Res 7: 39–44
Pratt CM, Welton DE, Squires WG, Kirby TE, Hartung GH, Miller RR (1981) Demonstration of training effect during chronic beta-adrenergic blockade in patients with coronary artery disease. Circulation 64 (6): 1125–1129
Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Prichard BNC (1964) Hypotensive action of pronethalol. Br Med J 1: 1227–1228
Prichard BNC (1971) Beta-receptor antagonists in angina pectoris. Ann Clin Res 3: 344–352
Prichard BNC (1974) Beta adrenergic receptor blocking drugs in angina pectoris. Drugs 7: 55–84
Prichard BNC (1978) Beta-adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol 5: 379–399
Prichard BNC (1982) Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension. Br J Clin Pharmacol 13: 51–60
Prichard BNC (1983) Mechanisms of myocardial infarct prevention with beta-adrenergic blocking drugs. Drugs 25 [Suppl 2]: 295–302
Prichard BNC, Boakes AJ (1977) The use of beta-adrenergic blocking drugs in hypertension: a review. Curr Med Res Opin 4 [Suppl 5]: 51–76
Prichard BNC, Gillam PMS (1966) Propranolol in hypertension. Am J Cardiol 18: 387–391
Prichard BNC, Gillam PMS (1969) Treatment of hypertension with propranolol. Br Med J 1: 7–16
Prichard BNC, Gillam PMS (1971) Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J 33: 473–480
Prichard BNC, Ross EJ (1966) Use of propranolol in conjunction with alpha-receptor blocking drugs in phaeochromocytoma. Am J Cardiol 18: 394–398
Prichard BNC, Vrhovac B (1975) Pharmacology of anti-anginal drugs. In: Harcus AW, Adamson L (eds) Arteries and veins. Churchill Livingston, London, pp 266–281
Prichard BNC, Dickinson CJ, Alleyne GAO, Hurst P, Hill ID, Rosenheim ML, Laurence DR (1963) Effect of pronethalol in angina pectoris. Br Med J 2: 1226–1227
Prichard BNC, Boakes AJ, Day GM (1971) Practolol in the treatment of hypertension. Postgrad Med J 47: 84–91
Prichard BNC, Owens CWI, Tuckman J (1980) Clinical features of adrenergic agonists and antagonists. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 559–697 (Handbook of experimental pharmacology, vol 54/ 2 )
Prichard BNC, Walden RJ, Markiewicz A, Richards GA (1981) Beta-adrenergic blockade in ischaemic heart disease. Br J Clin Pract 12: 12–28
Prichard BNC, Tomlinson B, Walden RJ, Bhattacharjee P (1983) The beta adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol 5: S56–S62
Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N (1959) Angina pectoris. 1. A variant form of angina pectoris. Am J Med 27: 375–388
Raftery EB, Denman AM (1973) Systemic lupus erythematosus syndrome induced by practolol. Br Med J 2: 452–455
Rainwater J, Steele P, Kirch D, LeFree M, Jensen D, Vogel R (1982) Effect of propranolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation 65: 77–81
Ranchod A, Keeton Gr, Benatar SR (1982) The effect of beta-blockers on ventilatory function in chronic bronchitis. S Afr Med J 62: 423–424
Rangno RE, Langlois S (1982) Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Am Heart J 104: 473–478
Raptis S, Rosenthal J, Welzel D, Moulopoulos S (1981) Effects of cardioselective and noncardioselective beta-blockade on adrenaline-induced metabolic and cardiovascular responses in man. Eur J Clin Pharmacol 20: 17–22
Rasmussen K, Andersen K, Wang H (1982) Atrial fibrillation induced by atenolol. Eur Heart J 3: 276–281
Rasmussen MM, Remer KA, Kloner RA, Jennings RB (1977) Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation 56: 794–798
Reeves PR, McAinsh J, Mcintosh DAD, Winrow MJ (1978) Metabolism of atenolol in man. Xenobiotica 8: 313–320
Reeves RL, Sen SB, Summit NJ (1982) The effect of metoprolol and propranolol on pancreatic insulin release. Clin Pharmacol Ther 31: 262–263
Regardh C-G, Johnsson G (1980) Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5: 557–569
Reichert N, Shibolet S, Adar R, Gafni J (1975) Controlled trial of propranolol in intermittent claudication. Clin Pharmacol Ther 17: 612–615
Religa A, Mueller HS, Evans R, Ayres SM (1973) Metabolic effect of propranolol on ischaemic tissue in human and experimental myocardial infarction. Clin Res 21: 954
Rhabkin R, Stables OP, Levin NW, Suzman MM (1966) Prophylactic value of propranolol in angina pectoris. Am J Cardiol 18: 370–380
Richards DA, Prichard BNC (1979) Clinical pharmacology of labetalol. Br J Clin Pharmacol 8: 89s–93s
Richards DA, Prichard BNC, Boakes AJ, Tuckman J, Knight EJ (1977) Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J 39: 99–106
Richtsmeier TE, Preston TA (1977) Drug management of stable angina pectoris. Postgrad Med J 62: 91–100
Rieckert H, Kattwinkel W, Riechelmann H, Kuss A, Sierau R (1982) Peripheral haemodynamic effects of beta adrenoceptor blocking drugs with ISA or relative beta t- selectivity at rest and during physical exercise. Br J Clin Pharmacol 13: 227S–228S
Riley AJ, Riley EJ (1981) The effect of labetalol and propranolol on the pressor response to sexual arousal in women. Br J Clin Pharmacol 12: 341–344
Robertson RM, Wood AJJ, Vaughn WK, Robertson D (1982) Exacerbation of vasotonic angina pectoris by propranolol. Circulation 65: 281–285
Robinson B, Pilkington T (1963) Effect of pronethalol in angina pectoris. Br Med J 2: 1227–1228
Robinson BF (1967) Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation 35: 1073–1083
Robinson BF (1968) Mode of action of nitroglycerin in angina pectoris. Correlation between haemodynamic effects during exercise and provocation of pain. Br Heart J 30: 295–302
Robinson BF (1971) The mode of action of beta-antagonists in angina pectoris. Postgrad Med J 47: 41–43
Robinson BF, Wilson AG (1968) Effect on forearm arteries and veins of attenuation of the cardiac response to leg exercise. Clin Sci 35: 143–152
Robson RD, Kaplan HR (1970) The cardiovascular pharmacology of bunolol, a new beta adrenergic blocking agent. J Pharmacol Exp Ther 175 (1): 157–167
Robson RH, Vishwanath MC (1982) Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J 284: 104
Rodger CJ, Sheldon CD, Lerski RA, Livingstone WR (1976) Intermittent claudication complicating beta blockade. Br Med J 1: 1125
Rose G (1982) Should every survivor of a heart attack be given a beta blocker? Part III: some conclusions. Br Med J 285: 39–40
Ross PJ, Jones MK, John R (1980) Thyroid hormone levels after propranolol withdrawal. Clin Sci 58: 22 P
Routledge PA, Shand DG (1979) Clinical pharmacokinetics of propranolol. Clin Pharmacokinet 4: 73–90
Roy P, Day L, Sowton E (1975) Effect of new beta adrenergic blocking agent, atenolol ( Tenormin) on pain frequency, trinitrin consumption and exercise ability. Br Med J 3: 195–197
Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE (1979) Selectivity of beta adrenoceptor antagonist drugs assessed by histamine provocation. Clin Pharmacol Ther 25: 536–540
Russek HI (1968) Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol 21: 44–54
Ryan JR, Lacorte W, Jain A, McMahon FG (1983) Response of diabetics treated with atenolol or propranolol to insulin-induced hypoglycaemia. Drugs 25 [Suppl 1]: 256–257
Sadick NN, Tan ARH, Fletcher PJ, Morris J, Kelly DT (1982) A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina. Circulation 66: 574–579
Sainani GS, Mukherjee AK (1972) A double-blind trial of LB 46 (Visken) in angina pectoris. Indian Heart J 24 [Suppl 1]: 192–196
Salvetti A, Arzili F, Pedrinelli R, Beggi P, Motolese M (1982) Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol 22: 197–201
Sandler G, Clayton GA (1970) Clinical evaluation of practolol, a new cardioselective beta blocking agent in angina pectoris. Br Med J 2: 399–402
Sandler G, Pistevos A (1972) Clinical evaluation of oxprenolol in angina pectoris. Br Heart J 34: 847–850
Sarnoff SA, Braunwald E, Welch GH, Case RB, Stainsby WN, Macruz R (1958) Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension time index. Am J Physiol 192: 148–151
Sarnoff SJ, Gilmore JP, Weisfeldt ML, Daggett WM, Mansfield PB (1965) Influence of norepinephrine on myocardial oxygen consumption under controlled hemodynamic conditions. Am J Cardiol 16: 217–226
Sas M, Kovacs L (1981) Systemic pharmacology of adrenergic activators and inhibitors: Effects on the genital system. In: Szekeres L (ed) Adrenergic activators and inhibitors. Springer, Berlin Heidelberg New York, pp 213–242 (Handbook of experimental pharmacology, vol 54/2)
Sassard J, Pozet N, McAinsh J, Legheand J, Zech P (1977) Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol 12: 175–180
Schlierf G, Papenberg J, Raetzer H (1973) The effect of l-(Indo-4-yl-oxy)-3-isopropylamino-propran-2-ol (LB-46 Visken) on carbohydrate and lipid metabolism. Eur J Clin Pharmacol 5: 154–157
Sehluter KJ, Aellig WH, Petersen K-G, Rieband H–CH, Wehrli A, Keip L (1982) The influence of beta adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia. Br J Clin Pharmacol 13: 407S–417S
Schrumpf JD, Sheps DS, Wolfson S, Aronson AL, Cohen LS (1977) Altered hemoglobin- oxygen affinity with long-term propranolol therapy in patients with coronary artery disease. Am J Cardiol 40: 76–82
Schwartz JB, Jackson G, Kates RE, Harrison DC (1981) Long-term benefit of cardioselective beta blockade with once daily atenolol therapy in angina pectoris. Am Heart J 101: 380–385
Scott ME, Balnave K (1980) Comparison of propranolol and Inderal LA in patients with angina. Ulster Med J 49: 79–84
Sealey BJ, Lijiedal J, Ablad B, Nyberg G (1969) The effects of intravenous alprenolol on exercise tolerance in patients with angina pectoris. Pharmacologica Clinica 2: 46–50
Sealey BJ, Lijiedal J, Nyberg G, Ablad B (1971) Acute effects of oral alprenolol on exercise tolerance in patients with angina pectoris. A dose response study. Br Heart J 33: 481–488
Shah RR, Oates NS, Idle JR, Smith RL (1982) Beta-blockers and drug oxidation status. Lancet 1: 508–509
Shand DG (1974 a) Individualisation of propranolol therapy. Med Clin North Am 58:1063–1069
Shand DG (1974 b) Pharmacokinetic properties of beta adrenergic receptor blocking drugs. Drugs 7:39–47
Shand DG (1976) The pharmacokinetics of propranolol: a review. Postgrad Med J 52: 22–25
Shand DG, Rangno RE (1972) The disposition of propranolol. I Elimination during oral absorption in man. Pharmacology 7: 159–168
Shand DG, Branch RA, Evans GH, Nies AS, Wilkinson GR (1973) The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver. Drug Metab Dispos 1: 679–686
Shell WE, Sobel BE (1973) Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol 31: 474–479
Shepherd AMM, Lin M-S, Keeton TK (1981) Hypoglycaemia - induced hypertension in a diabetic patient on metoprolol. Ann Intern Med 94: 357–358
Shinebourne E, Flemming J, Hamer J (1967) Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart disease. Lancet 2: 1217–1220
Shiroff RA, Mathis J, Zelis R, Schneck DW, Babb JD, Leaman DM, Hayes AH (1978) Propranolol rebound - a retrospective study. Am J Cardiol 41: 778–780
Shumway NE, Johnson JA, Stish RJ (1957) The study of ventricular fibrilation by threshold determinations. J Thorac Surg 34: 643–653
Silke B, Nelson GIC, Ahuja RC, Taylor SH (1982) Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease. Br Heart J 48: 364–371
Simonsen S (1977) Effect of atenolol (ICI 66082) on coronary haemodynamics in man. Br Heart J 39: 1210–1216
Singh BN, Jewitt DE (1974) Beta-adrenergic receptor blocking drugs in cardiac arrhythmias. Drugs 7: 426–461
Singh BN, Vaughan Williams EM (1970) A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39: 675–687
Sklar J, Johnston D, Overlie P, Gerber JG, Brammell HL, Gal J, Nies AS (1982) The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to dynamic exercise in normal men. Circulation 65: 894–899
Slome R (1973) Withdrawal of propranolol and myocardial infarction. Lancet 1: 156
Smith RS, Warren DJ (1982) Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. J Cardiovasc Pharmacol 4: 2–4
Sondodi S, Agabiti-Rosel E, Fraser R, Leckie BJ, Morton JJ, Cumming AMM, Sood BP, Robertson JLS (1982) Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol. Br J Clin Pharmacol 13: 341–350
Sonnenblick EH (1962) Implications of muscle mechanics in the heart. Fed Proc 21: 975–990
Sonnenblick EH, Skelton CL (1971) Myocardial energetics: basic principles and clinical implications. N Engl J Med 285: 668–675
Sonnenblick EH, Braunwald E, Williams JF, Glick G (1965) Effects of exercise in myocardial force - velocity relations in intact unaesthetised man: relative roles in change in heart rate, sympathetic activity and ventricular dimensions. J Clin Invest 44: 2051–2062
Sonnenblick EH, Ross J, Braunwald E (1968) Oxygen consumption of the heart. Newer concepts of its multifactorial determination. Am J Cardiol 22: 328–336
Sotaniemi EA, Pelkonen O, Arranto AJ, Sako S, Anttila M (1983) Effect of liver function on beta blocker kinetics. Drugs 25: 113–120
Southall E, Nutt NR, Thomas RD (1982) Chronic stable angina: comparison of verapamil and propranolol. J Int Med Res 10: 361–366
Sowton E, Smithen C (1971) Double-blind three-dose trial of oral alprenolol in angina pectoris. Br Heart J 33: 601–606
Sowton E, Smithen C, Leaver D, Barr I (1971) Effect of practolol on exercise tolerance in patients with angina pectoris. Am J Med 51: 63–70
Sponer G, Bartsch W, Strein K, Müller-Beckmann B (1982) The pharmacological profile of BM 14,190, a compound with beta-blocking and vasodilating properties. Naunyn-Schmiedebergs Arch Pharmacol 321 [Suppl R]: 21–81
Sponer G, Voss E, Dietmann K (1981) Wirkung von IS-5-MN, Metipranolol und deren Kombination auf die provozierte Myocardischamie bei wachen Hunden. Med Welt 32 (14 a): 492–496
Srivastava SC, Dewar HA, Newell DJ (1964) Double-blind trial of propranolol ( Inderal) in angina of effort. Br Med J 2: 724–725
Steele P, Gold F (1982) Favorable effects of acebutolol on exercise performance and angina in men with coronary artery disease. Chest 1: 40–43
Stephens J, Hayward R, Ead H, Adams L, Hamer J, Spurrell R (1978) Effects of selective and non selective beta-adrenergic blockade on coronary dynamics in man assessed by rapid atrial pacing. Br Heart J 40: 856–863
Storstein-Spilker L (1970) The influence of the beta-receptor blocking agent LB-46, isosorbide-dinitrate and their combination on the exercise ECG. Cardiovasc Res 4: 298 p
Svedmyr N, Malmberg R, Haggendal E (1970) The haemodynamic effects of sotalol (MJ 1999) and propranolol in man. Pharmacologica Clinica 2: 82–85
Svendsen TL, Hartling O, Trap-Jensen J (1979) Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers. Eur J Clin Pharmacol 15: 223–228
Svendsen TL, Hartling OJ, Trap-Jensen J, McNair A, Bliddal J (1981) Adrenergic beta receptor blockade, haemodynamic importance of intrinsic sympathomimetic activity at rest. Clin Pharmacol Ther 29: 711–718
Svensson A, Gudbrandsson T, Sivertsson R, Hansson L (1982) Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients. Br J Clin Pharmacol 13: 259S–267S
Sybertz EJ, Baum T, Pula KK, Nelson S, Eynon E, Crawford S (1982) Studies on the mechanism of the acute antihypertensive and vasodilator actions of several ß-adrenoceptor antagonists. J Cardiovasc Pharmacol 4: 749–758
Syvalahti E, Lammintausta R, Ilsalo E, Kanto J (1977) Cardioselective (metoprolol) and non-selective (propranolol) beta-blockade and glucose homeostasis. Ann Clin Res 9: 292–295
Taggart P, Carruthers M (1972) Suppression by oxprenolol of adrenergic response to stress. Lancet 2: 256–258
Taggart P, Carruthers M, Somerville W (1973) Electrocardiogram, plasma catecholamines and lipids and their modification by oxprenolol when speaking before an audience. Lancet 2: 341–346
Takenaka T, Asano M, Berdeaux A, Giudicelli J-F (1982) Adrenoceptor blocking, hemodynamic and coronary effects of YM-09538, a new combined alpha- and beta-adrenoceptor blocking drug, in anaesthethized dogs. Europ J Pharmacol 85: 35–50
Tarazi RC, Dustan HP (1972) Beta-adrenergic blockade in hypertension. Practical and theoretical implications of long term hemodynamic variations. Am J Cardiol 29: 633–640
Taylor JA (1968) Hypotension after oral propranolol. Lancet 1: 532–533
Taylor SH, Meeran MK ( 1973 b) The cardiovascular response to some environmental stresses and their modification by oxprenolol. In: Burley DM, Frier JH, Rondel RK, Taylor SH (eds) New perspectives in beta blockade. Ciba, Horsham, pp 293–306
Taylor SH, Silke B, Lee PS, Hilal A (1982) Haemodynamic dose-response effects of intravenous beta-blocking drugs with different ancillary properties in patients with coronary heart disease. Eur Heart J 3: 564–569
Textor SC, Fouad FM, Bravol EL, Tarazi RC, Vidt DG, Gifford RW (1982) Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med 307: 601–604
Thadani U, Parker JO (1979) Propranolol in angina pectoris: duration of improved exercise tolerance and circulatory effects after acute oral administration. Am J Cardiol 44: 118–125
Thadani U, Parker JO (1980) Propranolol in angina pectoris: comparison of therapy given two and four times daily. Am J Cardiol 46: 117–123
Thadani U, Sharma B, Meeran MK, Majid PA, Whitaker W, Taylor SH (1973) Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J 1: 138–142
Thompson FD, Joekes AM, Foulkes DM (1972) Pharmacodynamics of propranolol in renal failure. Br Med J 2: 434–436
Thulesius O, Gjores JE, Berlin E (1982) Vasodilating properties of beta adrenoceptor blockers with intrinsic sympathetic activity. Br J Clin Pharmacol 13: 229S–230S
Tjandramaga TB, Thomas J, Verbeeck R, Verbesselt R, Verberckmoes R, De Schepper PJ (1976) The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 3: 259–265
Toubes DB, Ferguson RK, Rice AJ, Aoki VS, Funk DC, Wilson WR (1970) Beta adrenergic blockade vs placebo in angina pectoris. Clin Res 18: 345
Trap-Jensen J, Clausen JP, Noel I, Larsen OA, Krosgaard AR, Christensen JN (1976) The effects of beta adrenoceptor blockers on cardiac output, liver blood flow and skeletal muscle blood flow in hypertensive patients. Acta Physiol Scand [Suppl] 440: 30
Trap-Jensen J, Carlsen JE, Svendsen TL, Christensen NJ (1979) Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. Eur J Clin Invest 9: 181–183
Trap-Jensen J, Carlsen JE, Hartling OJ, Svendsen TL, Tango M, Christensen NJ (1982) Beta adrenoceptor blockade and psychic stress in man. A comparison of the acute effects of labetalol, metoprolol, pindolol and propranolol on plasma levels of adrenaline and noradrenaline. Br J Clin Pharmacol 13: 391S–395S
Tremberlay G, Biron P, Caille G, Robert P, Fontaine R (1981) Double-blind crossover trial of single versus twice-daily doses of acebutolol in angina. Curr Ther Res 29: 644–650
Turi ZG, Braunwald E (1983) The use of beta-blockers after myocardial infarction. JAMA 249 (18): 12–16
Turner GG, Nelson RR, Nordstrom LA, Diefenthal HC, Gobel FL (1978) Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris. Br Heart J 40: 1361–1370
Turner GG, Weir EK, Chesler E, Pierpont GL (1981) Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol. Am J Cardiol 47: 910–916
Turner P (1983) Beta blockade and the human central nervous system. Drugs 25 [Suppl 2]: 262–264
Ulrych M, Frolich ED, Dustan HP, Page IH (1968) Immediate haemodynamic effects of beta-adrenergic blockade with propranolol in normotensive and hypertensive man. Circulation 37: 411–416
Vale JA, Jeffreys DB (1978) Peripheral gangrene complicating beta blockade. Lancet 1: 1216
Vandenburg MJ, Conlon C, Ledingham JM (1981) A comparison of the effects of propranolol and oxprenolol on forearm blood flow and skin temperature. Br J Clin Pharmacol 11: 48 5–90
Vandongen R, Davidson L, Beilin LJ, Barden AE (1981) Effect of beta adrenergic receptor blockade with propranolol on the response of plasma catecholamines and renin activity to upright tilting in normal subjects. Br J Clin Pharmacol 13: 369–374
Van-Herwaarden CLA, Binkhorst RA, Fennis JFM, Van’T Laar A (1979) Effects of propranolol and metoprolol on haemodynamic and respiratory indices and on perceived exertion during exercise in hypertensive patients. Br Heart J 41: 99–105
Vatner SF, Baig H, Manders WT, Ochs H, Pagani M (1977) Effects of propranolol on regional myocardial function, electograms and blood flow in conscious dogs with myocardial ischaemia. J Clin Invest 60: 353–360
Velasco M, Vizcarrondo H, Urbina-Quintana A, Hernandez-Pieretti O (1982) A comparative study between pindolol and nadolol on systemic and cardiac hemodynamics in hypertensive patients. Curr Ther Res 32: 663–668
Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR (1979) Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 26: 8–15
Vlachakis ND, Aledort L (1980) Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 45: 321–325
Von Bahr C, Collste P, Frisk-Holmberg M, Haglund K, Jorfelt L, Orme M, Ostman J, Sjoqvist F (1976) Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade and plasma renin activity in essential hypertension. Clin Pharmacol Ther 20: 130–137
von Mollendorff E, Huschka C, Schroter E, Abshagen U (1981) BM 12.434, a novel compound with vasodilating and ß-adrenoceptor blocking activities. Clin Sci 61: 477s–479s
Waal-Manning HJ (1970) Comparative studies on the hypotensive effects of beta-adrenergic receptor blockade. In: Simpson FO (ed) Symposium on beta-adrenergic receptor blocking drugs. Ciba, Auckland, p 64
Waal-Manning HJ (1976) Metabolic effects of beta adrenoceptor blockers. Drugs 11: 121–126
Waal-Manning HJ (1979a) Can beta blockers be used in diabetic patients? Drugs 17: 157–160
Waal-Manning HJ (1979 b) Atenolol and three nonselective beta blockers in hypertension. Clin Pharmacol Ther 25:8–18
Waal-Manning HJ, Simpson FO (1971) Practolol treatment in asthmatics. Lancet 2: 1264–1265
Wahlquist ML, Kaijser L, Lassers BW, Carslon LA (1973) Fatty acid as a determinant of myocardial substrate and oxygen metabolism in man at rest and during prolonged exercise. Acta Med Scand 193: 89–94
Walden RJ, Bhattacharjee P, Tomlinson B, Cashin J, Graham BR, Prichard BNC (1982) The effect of intrinsic sympathomimetic activity on beta receptor responsiveness after beta adrenoceptor blockade withdrawal. Br J Clin Pharmacol 13: 359S–364S
Walstad RA, Berg KJ, Wessel-Aas T, Nilsen OG (1982) Labetalol in the treatment of hypertension in patients with normal and impaired renal function. Acta Med Scand 665: 135–141
Wan SH, Koda RT, Maronde RF (1979) Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol 7: 569–574
Wasserman AJ, Proctor JD, Allen FJ, Kemp VE (1970) Human cardiovascular effects of alprenolol, a beta adrenergic blocker: haemodynamic, antiarrhythmic and antianginal. J Clin Pharmacol 10: 37–49
Watkins J, Abott EC, Hensby CN, Webster J, Dollery CT (1980) Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J 281: 702–705
Watson RDS, Eriksson B-M, Hamilton CA, Reid JL, Stallard TJ, Littler WA (1980) Effects of chronic beta-adrenoceptor antagonism on plasma catecholamines and blood pressure in hypertension. J Cardiovasc Pharmacol 2: 725–738
Wayne V, Harper R, Laufer E, Federman J, Anderson S, Pitt A (1982) Adverse interaction between oral beta adrenergic blocking drugs and verapamil. Aust NZ J Med 12: 312
Westerlund A (1982) Atenolol and timolol. N Engl J Med 307: 1343–1344
Wiener L, Dwyer EM, Cox JW (1969) Hemodynamic effects of nitroglycerin, propranolol, and their combination in coronary heart disease. Circulation 39: 623–631
Wilcox RG, Hampton JR (1982) Comparison between atenolol and nadolol in essential hypertension at rest and on exercise. Br J Clin Pharmacol 13: 841–846
Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchell JRA (1980) Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J 281: 885–888
Wiles WJ, Peduzzi PN, Hammond G (1977) Preoperative predictors of operative mortality for coronary by-pass in patients with unstable angina pectoris. Am J Cardiol 39: 939–943
Wilhelmsen L, Wedel H, Tibblin G (1973) Multivariate analysis of risk factors for coronary heart disease. Circulation 48: 950–958
Wilhelmsson C, Vedin J A, Wilhelmsen L, Tibblin G and Werko L (1974) Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Lancet 2: 1157–1160
Williams LT, Lefkowitz RJ (1978) Receptor binding studies in adrenergic pharmacology. Raven, New York
Wilson AG, Brooke OG, Lloyd HF, Robinson BF (1969) Mechanism of action of betaadrenergic receptor blocking agents in angina pectoris; comparison of action of propranolol with dexpropranolol and practolol. Br Med J 4: 399–401
Winer N, Chokshi DS, Yoon MS, Freedman AD (1969) Adrenergic receptor mediation of renin secretion. J Clin Endocrinol Met 29: 1168–1175
Wiseman RA (1971) Practolol-accumulated data on unwanted effects. Postgrad Med J 47: 68–71
Wolfson S, Gorlin R (1969) Cardiovascular pharmacology of propranolol in man. Circulation 40: 501–511
Wolfson S, Heinle RA, Herman MN, Kemp HG, Sullivan JM, Gorlin R (1966) Propranolol in angina pectoris. Am J Cardiol 18: 345–353
Woods KL, Linton SP, Kendall MJ, Faragher EB, Grieve RJ (1979) Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta blockers. Eur J Clin Pharmacol 15: 229–233
Wray R, Sutcliffe SB J (1972) Propranolol induced hypoglycaemia and myocardial infarction. Br Med J 2: 592
Wright AD, Barber SG, Kendall MJ, Poole PH (1979) Beta-adrenoceptor blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1: 159–161
Wright P (1975) Untoward effects associated with practolol administration: oculumucocutaneous syndrome. Br Med J 1: 595–598
Yasue H, Omote S, Takizawa A, Nagao M, Miwa K, Kato H, Tanaka S, Akiyama F (1978) Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs. Jpn Circulation J 42: 1–11
Yitibasi O, Nalbantgil I (1970) Essai d’un nouveau beta-bloquer le LB 46, dans le traitement de Pangine de poitrine. Praxis 59: 1218–1221
Yusuf S, Ramsdale D, Peto R, Furse L, Bennett D, Bray C, Sleight P (1980) Early intravenous atenolol in suspected acute myocardial infarction. Lancet 2: 273–276
Yusuf S, Rossi P, Ramsdale D, Peto R, Furse L, Motwani R, Parish S, Gray R, Bennett D, Bray C, Sleight P (1983) Reduction in infarct size, arrhythmias, chest pain and morbidity by early intravenous beta-blockade in suspected acute myocardial infarction. Drugs 25 [Suppl 2]: 303–307
Zacharias FJ, Co wen KJ, Vickers J, Wall BG (1972) Propranolol in hypertension. A study of long term therapy 1964–1970. Am Heart J 83: 755–761
Zaman R, Kendall MJ (1982) The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol 13: 507–512
Zito RA, Cassell I, Cunningham M, Gradman AH, Ross AM, Zaret BL (1980) High dose propranolol in the treatment of angina pectoris: relationship of dose to blood levels and hemodynamic consequences. Yale J Biol Med 53: 173–179
Zsoter TT, Beanlands DS (1969) Propranolol in angina pectoris. Arch Intern Med 124: 584–587
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Prichard, B.N.C. (1985). β-Adrenoceptor Blocking Agents. In: Abshagen, U. (eds) Clinical Pharmacology of Antianginal Drugs. Handbook of Experimental Pharmacology, vol 76. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69524-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-69524-7_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-69526-1
Online ISBN: 978-3-642-69524-7
eBook Packages: Springer Book Archive